Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay.

Abstract

Quantitation of hepatitis C virus (HCV) RNA has become an important tool in different clinical settings and is used extensively for pretreatment evaluation of patients infected chronically with HCV. In this study, the performance characteristics of the third generation branched DNA-based signal amplification assay (bDNA 3.0) for HCV RNA quantitation were established. The new assay version showed an analytical specificity of 98%. Mean intra- and between-run imprecisions were 6.8 and 11.2%, respectively. The assay was linear over its entire dynamic range. Quantitation appeared to be unaffected by the genotypic variability of HCV. A comparison of bDNA 3.0 with the second generation bDNA assay calibrated against the international WHO HCV RNA standard, and the PCR-based Cobas Amplicor HCV Monitor 2.0 revealed a fairly good correlation among the assays. Twenty-nine and 11% of the paired quantitative results differed by more than log(10)0.5 (i.e. three-fold). All three assays after calibration against the WHO standard also yielded clinically comparable results with regard to the tailoring of interferon alpha/ribavirin treatment duration in patients infected by HCV genotypes 1, 4, and 5.

Cite this paper

@article{Ross2002QuantitationOH, title={Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay.}, author={Rudolf Stefan Ross and Sergei O Viazov and Sokavuth Sarr and Stanislaw Hoffmann and Angela Kramer and Michael Roggendorf}, journal={Journal of virological methods}, year={2002}, volume={101 1-2}, pages={159-68} }